Earnings Insights
AI-generated analysis of quarterly earnings, concall highlights, and financial performance across Indian listed companies.
How to use these insights
Each article is built from earnings call transcripts and structured rank signals. Start with the latest summary, then open the stock page for the full company view, the concall page for quarter-by-quarter commentary, and the rankings dashboard to compare peers.
Krsnaa Diagnost. Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
600-1,000 crores sales from retail alone. Key concall takeaways from Krsnaa Diagnost.'s Q2 FY26 earnings call — and how it ranks against sector peers.
5 Aug 2026
Krsnaa Diagnost. Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
EBITDA grew by 19% YoY to INR 524 million with a 120 bps margin expansion to 27%. Key concall takeaways from Krsnaa Diagnost.'s Q1 FY26 earnings call — and how…
5 Aug 2026
Krsnaa Diagnost. Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
FY25 revenue grew 16% YoY to INR 7,172 million; EBITDA rose 34% to INR 1,958 million with a 27% margin; net profit up 37% to INR 776 million with 11% margin…
5 Aug 2026
Aptus Value Housing Finance India Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
Disbursement growth was 24% Q-on-Q in Q2 FY'26, showing strong recovery despite challenges. Key concall takeaways from Aptus Value Housing Finance India Ltd's…
5 Aug 2026
Eternal Q3 FY26 earnings call: Revenue & Margins | Arthneeti
Q3 FY26
They remain focused on maintaining strong contribution margins (~5-6% of NOV) across city tiers. Key concall takeaways from Eternal Ltd's Q3 FY26 earnings call…
5 Aug 2026
Eternal Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
Conservative geographic expansion planned, focusing on high-profit areas (~top 40% of addressable market), with cautious scaling until more data is available…
5 Aug 2026
Eternal Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
. Key concall takeaways from Eternal Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
5 Aug 2026
Eternal Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
Working capital investments are significant, cited as approximately INR 1,000 crore, roughly representing 15 days of inventory; this could increase if they…
5 Aug 2026
Rolex Rings Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
Incremental orders worth ~175 crore likely to start contributing from Q2 FY26, boosting revenues (Hiren, 00:44:45). Key concall takeaways from Rolex Rings…
5 Aug 2026
Rolex Rings Q3 FY25 earnings call: Revenue & Margins | Arthneeti
Q3 FY25
Total incremental business of approximately ₹175 crores is planned for FY 26 from new customers and programs. Key concall takeaways from Rolex Rings Ltd's Q3…
5 Aug 2026
Alivus Life Sciences Q3 FY26 earnings call: Revenue & Margins | Arthneeti
Q3 FY26
Mature molecules show stable volumes with 2-3% growth, while newer launches and upcoming patent expiries offer significant volume expansion opportunities. Key…
5 Aug 2026
Alivus Life Sciences Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
Earnings:** PAT margin for FY’25 stood at 20.3%, with Q4 FY’25 PAT margin at 21.8%, indicating steady profit growth. Key concall takeaways from Alivus Life…
5 Aug 2026
Alivus Life Sciences Q3 FY25 earnings call: Revenue & Margins | Arthneeti
Q3 FY25
Volume growth for Q3 FY'25 was strong at about 18%, despite a ~6% price erosion. Key concall takeaways from Alivus Life Sciences Ltd's Q3 FY25 earnings call…
5 Aug 2026
Tatva Chintan Pharma Chem Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
Goods in transit for the PASC (Phase Transfer Catalysts) segment have increased from INR16-17 crores last quarter to INR26 crores this quarter, reflecting an…
5 Aug 2026
Tatva Chintan Pharma Chem Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
Capex plan for FY '26: approximately INR 110 crores to support growth and new product lines. Key concall takeaways from Tatva Chintan Pharma Chem Ltd's Q1 FY26…
5 Aug 2026
Tatva Chintan Pharma Chem Q3 FY25 earnings call: Revenue & Margins | Arthneeti
Q3 FY25
Revenue potential could surpass INR 900 crores with existing and upcoming capacities by 2026. Key concall takeaways from Tatva Chintan Pharma Chem Ltd's Q3…
5 Aug 2026
GMR Airports Q3 FY25 earnings call: Revenue & Margins | Arthneeti
Q3 FY25
Robust traffic growth despite aircraft supply constraints, with aircraft operating above 85-90% load factors. Key concall takeaways from GMR Airports Ltd's Q3…
5 Aug 2026
Clean Science & Technology Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
Domestic market (mainly HALS) grew 13% in H1 FY26; still room to expand customer base with 70-75% capacity utilization for food-grade antioxidants. Key concall…
5 Aug 2026
G R Infraprojects Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
2,800 crores EPC value pending. Key concall takeaways from G R Infraprojects's Q2 FY26 earnings call — and how it ranks against sector peers.
5 Aug 2026
G R Infraprojects Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
As of Q4 FY25, G R Infraprojects Limited's order book stood at INR 24,346 crores. Key concall takeaways from G R Infraprojects Ltd's Q4 FY25 earnings call…
5 Aug 2026